Empowered Patient Podcast

Chris Paradise, VP of Research and Development at Rion, is taking an acellular approach to developing next-generation regenerative medicines to treat degenerative diseases. The proprietary Rion system PEP, purified exosome product, uses extracellular vesicles or exosomes isolated from human blood platelets to send regenerative messages to cells to stimulate faster healing. This regenerative therapeutic allows for the administration in various forms, such as nebulization for pulmonary conditions and topical application for wounds. Chris explains, "What our focus has shifted towards at Rion is now an acellular approach, so it doesn't involve the use of cells or other components that have been proposed in the past. But we're focusing on extracellular vesicles or exosomes, and we can discuss those in more detail in a minute. But the point of emphasis is that it overcomes many of the limitations the field has previously faced. We're excited to offer reproducible, consistent, and, most importantly, accessible and a